Tobacco Industry Settles With States

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 12
Volume 7
Issue 12

WASHINGTON-As Oncology News International went to press, the tobacco industry and more than 40 state attorneys general were in final negotiations of a settlement worth approximately $206 over 25 years. The settlement will reimburse the states for Medicare spending on smoking-related illnesses, place some limits on cigarette advertising, and result in a substantial increase in cigarette prices. Look for a full analysis of the settlement in the January issue.

WASHINGTON—As Oncology News International went to press, the tobacco industry and more than 40 state attorneys general were in final negotiations of a settlement worth approximately $206 over 25 years. The settlement will reimburse the states for Medicare spending on smoking-related illnesses, place some limits on cigarette advertising, and result in a substantial increase in cigarette prices. Look for a full analysis of the settlement in the January issue.

Articles in this issue
Long-Term Adjuvant Tamoxifen Urged for Low-Risk Breast Cancer
EORTC DCIS Study Confirms Recurrence Reduction With RT
James Cancer Center Joins NCCN Outcomes Database
Managed Care Sees Need for National Guidelines, Accreditation
Advisory Panel Recommends Approval of Vysis HER2 Test
Drinking Tea After Smoking May Reduce Oxidative Stress
Roswell Park and Local HMO Use Claims Data to Study Regional Breast Cancer Care Patterns to Evaluate Quality
Use Special Skills, Tools to Assess Pain in Children, Elderly
Good Response Rates With Radiolabeled Anti-CD20 MoAB in NHL
Tobacco Industry Settles With States
Komen Foundation 1998 Awards Honor Leaders in Fight Against Breast Cancer
Dose Intensity, Density Increased in Breast Cancer
Full FDA Approval for Camptosar
CRFA Presents Frontlines Awards for Breast Cancer Awareness
Panel Recommends FDA Approval of DepoCyt

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.
1 expert in this video
1 expert in this video
1 expert in this video
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Related Content
Diagnostic developments using aberrances in biomarker testing may help enhance survival in patients with rare lymphoma subtypes.

Elucidating the Clinical Landscape for Rare Lymphoma Treatment

Roman Fabbricatore
April 17th 2025
Article

Diagnostic developments using aberrances in biomarker testing may help enhance survival in patients with rare lymphoma subtypes.

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Rad Onc First to Dose 177Lu in US, Notes Enormity of Recent mCRPC Approval

Rad Onc First to Dose 177Lu in US, Notes Enormity of Recent mCRPC Approval

Ariana Pelosci
April 17th 2025
Article

After the recent approval of 177Lu in PSMA+/mCPRCP prior to chemotherapy, Steven Finkelstein, MD, DABR, FACRO, highlights the importance of this milestone.

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

No treatment-related discontinuations have been observed related to Bria-IMT treatment for hormone receptor–positive breast cancer.

Bria-IMT Enhances Survival vs Sacituzumab Govitecan in HR+ Breast Cancer

Roman Fabbricatore
April 17th 2025
Article

No treatment-related discontinuations have been observed related to Bria-IMT treatment for hormone receptor–positive breast cancer.

Three Things You Should Know About Advances in Gastroesophageal Adenocarcinoma Therapy

Three Things You Should Know About Advances in Gastroesophageal Adenocarcinoma Therapy

ONCOLOGY Staff
April 17th 2025
Article

Immunotherapy combinations and targeted therapy options may help bridge clinical gaps in early-stage, locally advanced, and metastatic gastroesophageal adenocarcinomas.